Table 3.
Primary and secondary outcomes of the SMS Turkey trial.
|
|
PPA | ITT analysis | |||||||
| Control (n=27) % (n) |
Intervention (n=34) % (n) |
Relative risk (95% CI) |
Risk difference (95% CI) |
Control (n=75) % (n) |
Intervention (n=76) % (n) |
Relative risk (95% CI) |
Risk difference (95% CI) |
||
| Primary outcome |
|
|
|
|
|
|
|
|
|
|
|
CO-verified sustained abstinence at 3 months | 15 (4) | 24 (8) | 1.6 (0.53-4.7) | 0.09 (-0.11-0.28) | 5 (4) | 11 (8) | 2.0 (0.62-6.3) | 0.05 (-0.03-0.14) |
| Secondary outcomes |
|
|
|
|
|
|
|
|
|
|
|
CO-verified 7-day point prevalence abstinence at 4 weeksa | 12 (7) | 15 (9) | 1.3 (0.52-3.3) | 0.04 (-0.09-0.16) | 9 (7) | 12 (9) | 1.3 (0.50-3.2) | 0.03 (-0.07-0.12) |
|
|
Self-reported 7-day point prevalence abstinence at 3 months | 15 (4) | 29 (10) | 2.0 (0.70-5.6) | 0.15 (-0.06-0.35) | 5 (4) | 13 (10) | 2.5 (0.81-7.5) | 0.08 (-0.01-0.17) |
|
|
Self-reported 30-day point prevalence abstinence at 3 months | 15 (4) | 24 (8) | 1.6 (0.53-4.7) | 0.09 (-0.11-0.28) | 5 (4) | 11 (8) | 2.0 (0.62-6.3) | 0.05, (-0.03-0.14) |
a4-week PPA n=119 (ie, the 59 intervention and 60 control participants who provided cessation data at 4-weeks)